

2023


YEAR IN REVIEW

We grew thanks to you

Drug spend

28% increase in drug spend under management (*new Reformulary clients*)

28%



80%

Specialty drug reviews

80% increase in use of *myRequest* Services for specialty drug reviews



Good value is worth sharing



Clients achieved **13.5%** in savings

Per member per year drug spend

1.3% inflation rate in per member per year (PMPY) drug spend compared to 3.5% for private market¹




2,265%

Return on investment

2,265% Client return-on-investment from implementation to 2023²

Seamless transition, strong results



75% biosimilar penetration³

Reformulary plan members transitioned to biosimilars




Top trends

Managing [in]appropriate use of Ozempic®


Our evidence-based changes to coverage of Ozempic decreased off-label use of Ozempic. Within a few months:

- 60% decrease in off-label spend
- 41% decrease in number of claimants using Ozempic off-label⁴



Claimants

Spend



Optimally managing specialty spend

1.7% growth in Reformulary specialty drug spend compared to 12.9% growth in private market specialty drug spend

Recap




Expert reviews

Our 10 dedicated Expert Committee members reviewed & advised on over 50 drug evaluations

Successful adoption


90.4% generic penetration rate



Diversity, Equity, Inclusion.



7 Nationalities



11 Languages

Footnotes

1. Analytics database comprising 2.2 billion data records for public and private drug plans Canada-wide
2. Based on top clients from implementation to 2023
3. Claims for biosimilar in lieu of originator Biologic
4. Off-label means that a drug is not being used for the approved indication (use) by Health Canada